Validation of the MCL35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network
暂无分享,去创建一个
A. Rosenwald | W. Klapper | E. Hoster | D. Scott | A. Mottok | L. Rimsza | G. Ott | H. Holte | C. Thorns | H. Kluin-Nelemans | M. Dreyling | O. Hermine | M. Unterhalt | S. Hartmann | G. Rymkiewicz | Hilka Rauert-Wunderlich
[1] E. Giné,et al. A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome. , 2018, Blood.
[2] A. Rosenwald,et al. Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network. , 2018, Blood.
[3] S. Rule,et al. What is the optimal initial management of the younger mantle cell lymphoma patient? , 2017, Best practice & research. Clinical haematology.
[4] C. Portell,et al. Novel therapies for relapsed/refractory mantle cell lymphoma. , 2017, Best practice & research. Clinical haematology.
[5] J. Doorduijn,et al. What is the optimal initial management of the older MCL patient? , 2017, Best practice & research. Clinical haematology.
[6] E. Giné,et al. A new molecular assay and genomic complexity predict outcome in conventional and leukemic non-nodal mantle cell lymphoma , 2018 .
[7] R. Gascoyne,et al. Observation as the initial management strategy in patients with mantle cell lymphoma , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] J. Vose. Mantle cell lymphoma: 2017 update on diagnosis, risk‐stratification, and clinical management , 2017, American journal of hematology.
[9] D. Scott,et al. HIGH PROLIFERATION (MCL35 ASSAY) IS ASSOCIATED WITH INFERIOR OUTCOMES IN PATIENTS TREATED WITH INTENSIVE REGIMENS—A CORRELATIVE STUDY FROM THE CALGB 50403 (ALLIANCE) TRIAL , 2017 .
[10] L. Staudt,et al. New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] M. Ladetto,et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] A. Rosenwald,et al. Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] W. Klapper,et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network , 2016, The Lancet.
[14] J. Byrd,et al. Non-Hodgkin's lymphomas, version 4.2014. , 2014, Journal of the National Comprehensive Cancer Network : JNCCN.
[15] E. Kimby,et al. Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma. , 2014, Blood.
[16] W. Klapper,et al. Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] E. Kimby,et al. Nordic MCL 3 study : 90 Y-ibritumomab-tiuxetan added to BEAM / C in non-CR patients before transplant in mantle cell lymphoma , 2014 .
[18] E. Campo,et al. Molecular pathogenesis of mantle cell lymphoma. , 2012, The Journal of clinical investigation.
[19] W. Klapper,et al. Treatment of older patients with mantle-cell lymphoma. , 2012, The New England journal of medicine.
[20] E. Kimby,et al. Nordic MCL2 trial update: six‐year follow‐up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem‐cell support: still very long survival but late relapses do occur , 2012, British journal of haematology.
[21] J. Vose. Mantle cell lymphoma: 2012 update on diagnosis, risk‐stratification, and clinical management , 2012, American journal of hematology.
[22] Jeroen van der Laak,et al. Ki-67 as a prognostic marker in mantle cell lymphoma—consensus guidelines of the pathology panel of the European MCL Network , 2009, Journal of hematopathology.
[23] W. Klapper,et al. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. , 2008, Blood.
[24] Martin Dreyling,et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. , 2006, Blood.
[25] Andrew Lister,et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications--a study from the Lunenburg Lymphoma Biomarker Consortium. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] A. Rosenwald,et al. The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma. , 2006, Blood.
[27] W. Klapper,et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network , 2005, British journal of haematology.
[28] L. Staudt,et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. , 2003, Cancer cell.
[29] M. Williams,et al. Cyclin D1 overexpression in non-Hodgkin's lymphoma with chromosome 11 bcl-1 rearrangement. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.
[30] M. Raffeld,et al. bcl-1, t(11;14), and mantle cell-derived lymphomas. , 1991, Blood.